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Abstract
Background: In Germany, Iscucin
® Populi (IP), a preparation from mistletoe growing on the poplar tree, is used in
cancer therapy while Viscum Mali e planta tota (VM), a preparation from mistletoe growing on the apple tree, is
used in patients with osteoarthritis. Since mistletoe preparations are suspected to induce production of potentially
tumor promoting cytokines like interleukin (IL)-6, further studies on the immunological effects are of interest.
Methods: In this 3-armed randomized, double blind clinical trial healthy volunteers received increasing doses of
either IP (strength F, 0.0125%, G, 0.25% and H, 5%, each for 4 weeks), or VM (1:1000 [D3], 1:100 [D2] and 2% each
for 4 weeks) or placebo (isotonic solution) subcutaneously twice per week over a period of 12 weeks. Physical
examination was performed weekly. Routine laboratory parameters and immunological parameters (C-reactive
protein (CRP), differential blood count, lymphocyte subsets, immunoglobulins, IL-6 and tumor necrosis factor (TNF)-
a) were analysed every 4 weeks.
Results: 71 subjects were included in the study (IP = 30, VM = 21, placebo = 20) of whom 69 concluded it
according to protocol. Application of IP strengths G and H caused strong local reactions at the site of injection. In
parallel, a distinct eosinophilia (p < 0.001 compared to placebo) occurred. Furthermore, application of all IP
concentrations resulted in an increase of CD4 cell counts (p < 0.05) compared to placebo. Stimulation of IL-6
production, CRP or relevant deviations in other laboratory parameters were not observed. Because of local
reactions, IP strengths G and H were considered less tolerable than placebo. VM 2% was slightly less tolerable than
placebo, caused only mild local reactions and an only small increase in eosinophile counts.
Conclusion: Treatment with IP results in eosinophilia and an increase of CD4 cells but not in an increase of IL-6 or
CRP. No safety concerns regarding the two mistletoe preparations have been raised by this study. EudraCT-Number
2007-002166-35.
Trial registration: ClinicalTrials.gov: NCT01378702
Background
Mistletoe preparations are widely used among cancer
patients in Europe [1,2]. Increasing evidence exists, that
mistletoe preparations containing mistletoe lectins (ML)
have beneficial effects on the quality of life of cancer
patients during chemo- or radiation therapy [3]. Because
they can stimulate the production of interleukin (IL)-6
in periphereal mononuclear cells and lymphoma cells in
vitro it has been hypothesized, that they promote tumor
enhancement of related malignancies [4,5]. IL-6 is an
important growth factor for lymphoma and multiple
myeloma cells in vitro and in vivo [6]. However, in vitro
experiments incubating mistletoe extracts with lym-
phoma and multiple myeloma cells have shown dose
dependent apoptosis mediated growth inhibition and no
stimulation [7-9]. Furthermore, a retrospective study of
700 lymphoma patients who received mistletoe extracts
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hint for tumor promoting effects [10]. Nevertheless, the
German regulatory authority (BfArM, Federal Institute
for Drugs and Medical Devices) demanded further stu-
dies to prove safety.
Iscucin
® Populi (IP) and Viscum Mali e planta tota
(VM) are two mistletoe preparations that have been
used in anthroposophical medicine for decades in Ger-
many [11-13]. IP is registered for complementary cancer
therapy [11,12]. VM is used to reduce pain and improve
mobility in patients with arthropathies [13]. The study
was performed in order to fulfil the requirements of the
BfArM.
Because cancer patients are a heterogeneous collective
in whom effects of mistletoe treatment on immune
function and safety are compromised by the underlying
disease and/or conventional therapies healthy volunteers
were recruited for the clinical trial. The decisive advan-
tage of this setup is that healthy volunteers are a com-
parably homogenous collective with respect to their
immune system and that concomitant medication can
be excluded.
Methods
The trial was performed as a multiple dose, randomized,
placebo-controlled, double blind, monocenter dose esca-
lation clinical trial at University Medical Center Frei-
burg. The primary outcome criterion was to describe
the safety of IP and VM (adverse events: changes in
vital signs, physical examination and routine laboratory).
Secondary endpoints were the effects of IP and VM on
the immune system (interleukin (IL)-6, C-reactive pro-
tein, differential blood count, lymphocyte subsets (total
lymphocytes (CD3), CD4 cells, CD8 cells, B (CD19)
cells, natural killer (CD56) cells), tumor necrosis factor
(TNF)-a, immunoglobulins A, G, M, mistletoe antibo-
dies) and estimation of tolerability on a four point rating
scale (bad, moderate, good, excellent)
Healthy male and female volunteers between 18-45
years of age with a body mass index (BMI) between
18.5-28 kg/m
2, normal blood pressure, normal physical
examination and normal routine laboratory values (hae-
matology, coagulation parameters, creatinine, urea, uric
acid, electrolytes, creatine kinase, liver enzymes, lactate
dehydrogenase, bilirubin, total protein, albumin, alpha
amylase, lipids, glucose), negative Hepatitis B, C and
HIV serology, negative urine screen for drug abuse and
no ethanol in blood were included in the study. Exclu-
sion criteria were presence or sequelae of any clinically
significant disease, drug abuse, smoking more than 20
cigarettes a day, any medication in the week before
inclusion, participation in another clinical trial in the 3
preceding months, previous therapy with mistletoe pre-
parations, history of allergy to medicinal products,
donation of blood in the 3 preceding months, pregnancy
or breast-feeding, absence of highly effective contracep-
tion and inability to understand the nature and extent
of the trial.
Only volunteers who had given written informed con-
sent and met all the eligibility criteria were included
into the study. The study had a positive vote from the
ethics committee of the Faculty of Medicine at the
Albert-Ludwigs University of Freiburg (Germany) and
was carried out in compliance with the principles of
Good Clinical Practice and the Declaration of Helsinki.
At baseline the subjects were randomly assigned to IP,
VM or placebo. The subjects injected increasing doses
of either IP (strength F, 0.0125%, G, 0.25% and H, 5%,
each for 4 weeks) or VM (1:1000 [D3], 1:100 [D2] and
2% each for 4 weeks) or placebo subcutaneously in the
abdomen twice per week (interval 3 and 4 days) for a
period of 12 weeks. One ampoule of IP strength H was
regarded as the maximum tolerated dose, because it was
expected to cause strong local reactions [14,15]. In case
of strong local reactions dose reductions could be per-
formed analogously to the procedure used in tumor
patients in the sequence: ½ ampoule, ¼ ampoule, ⅛
ampoule, until subjective tolerability was achieved. 50%
of the injections were administered under supervision of
a study nurse or physician. The respective medication
for the next 4 weeks was handed out at baseline, after 4
weeks and after 8 weeks. Clinical and safety controls
(physical examination, inspection of the injection site)
were performed weekly. Routine laboratory parameters
(see above), immunological parameters (see above) and
estimation of tolerability (bad, moderate, good, excel-
lent) by the subjects were documented every 4 weeks
a l w a y si nt h em o r n i n gt ot h es a m et i m e( ±1h o u r )a s
baseline investigations. Mistletoe antibodies were deter-
mined in week 12. Safety and immunological parameters
were checked again in a follow up visit 4 weeks after the
last injection, The stepwise increase in dosage was per-
formed because we hypothesized an increase of side
effects and potential stimulation of the immune system
with the dosage. According to this hypothesis, low
dosages (strength F of IP, all dosages of VM) of the two
mistletoe preparations should be well tolerable and
cause only mild immunological changes as described in
a similar study investigating a different mistletoe pre-
paration [16]. Because of the high content of cytotoxic
mistletoe lectin in IP strength G and H, we expected
higher rates of side effects in the groups receiving IP
strength G and H.
Study medication
Iscucin
® Populi (IP) is an aqueous extract from mistle-
toes growing on poplar trees. The dried plant is
extracted with isotonic solution over a 14 day period
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centration 1:20 (5%, strength H) contains 50 mg of the
mother extract; concentration 1:400 (0.25%, strength G)
contains 2.5 mg and concentration 1:8000 (0.0125%,
strength F) 0.125 mg, respectively.
V i s c u mM a l iep l a n t at o t a( V M )i sa na q u e o u sf e r -
mented extract from fresh mistletoes growing on apple
trees. 1 ampoule (1 ml) of the concentration 1:1000
(third decimal, D3, according to the German homeo-
pathic pharmacopoeia) contains 1 mg of the mother
extract, concentration 1:100 (second decimal, D2) 10 mg
and concentration 2:100 (2%) 20 mg. Placebo was the
isotonic solution that is used for the preparation of IP
and VM consisting of sodium chloride, sodium bicarbo-
nate and water for injection.
Laboratory parameters
Routine laboratory parameters were analyzed within less
than 1 h of taking the probes by standard methods at
the central laboratory of University Medical Center Frei-
burg according to Good Laboratory Practice (GLP). C-
reactive protein (CRP) was determined using a turbidi-
metric, latex enhanced immunoassay. Lymphocyte sub-
sets were analyzed by flow cytometry (FACS Calibur,
Becton Dickinson, Heidelberg, Germany), using anti-
CD3, CD4, CD8, CD19 and CD56 monoclonal antibo-
dies (Becton Dickinson, Heidelberg, Germany).
For analysis of IL-6, TNF-a, mistletoe lectin- and vis-
cotoxin antibodies blood was centrifugated at 3000 g/
min for 5 min and sera were stored at -18°C at the clini-
cal trial centre until analyses at the end of the study. IL-
6a n dT N F - a were determined by ELISA at the central
laboratory of the University Medical Center Freiburg.
Mistletoe antibodies were determined by ELISA as
described in [17] at the Department of Internal Medi-
cine II of Tübingen University Hospital, Germany.
All analyses were performed blinded.
Statistics
The primary analysis was done on the safety population,
defined as all subjects who had received at least one
ampoule of the study medication and was identical to
the intention to treat analysis. All primary analysis was
descriptive. For categorical variables number and per-
centage were calculated, for continuous variables mean,
standard deviation, median, minimum and maximum
were presented. Courses of laboratory parameters were
analysed by generalised estimation equations (GEE),
hereby modeling treatment group and visit number as
fixed cofactors, the respective baseline value as a linear
covariate and the patient identification as the repeated
measurement factor. The correlation structure between
the visits was assumed to be first-order autoregressive.
All estimated group differences (IP versus placebo and
VM versus placebo) were based on these GEE models.
Tolerability was analysed by exact two-sided Wilcoxon-
Mann-Withney tests. The significance level was set to
0.05. As usual for safety studies, no correction for multi-
ple testing was performed.
Randomisation was performed by the biometrical cen-
tre (DatInf GmbH, Tübingen, Germany) using block
randomisation with variable block size. Allocation to the
groups was concealed. Blinding was performed by the
manufacturer. All ampoules were identically labelled
and packed in boxes with identical appearance. All ana-
lyses and data management were performed blinded.
As this was a modified phase I dose escalation study
20 subjects per group have been planned in analogy to
similar studies with other mistletoe preparations [16,18].
Because a higher drop-out rate and greater number of
side effects were expected in the IP group due to high
concentrations of especially mistletoe lectins (ML), 30
subjects were chosen for this group to make sure that at
least 20 could be analyzed.
Results
99 subjects were screened and 71 were randomised. 27
subjects were either screening failures or withdrew their
consent; one subject was included but not randomised
because of a common cold at baseline (visit 1, Figure 1).
70 of 71 subjects concluded the study, one in the VM
group stopped prematurely (after the first injection),
because she moved to a distant city 800 km from the
study centre. One subject from the placebo group was
excluded from the per protocol analysis because of
major protocol violations. Therefore, the per protocol
analysis comprised 69 subjects and the intention to treat
analysis 71 subjects. Table 1 shows the characteristics of
the subjects. There were no significant differences
between the groups at baseline.
Analysis of the immunological parameters revealed a
strong and significant eosinophilia following injection of
IP compared to baseline and placebo (Table 2, p =
0.006 in week 4, p < 0.001 in week 8 and 12). At follow
up eosinophil counts were back to baseline values. VM
resulted in an only small but also significant increase of
eosinophil counts (Table 2, p = 0.019 and p = 0.009
compared to placebo in week 8 and 12, respectively).
The increase in eosinophil counts in the IP group was
paralleled by the number of total leukocytes (p = 0.038
and p = 0.043 in week 8 and 12 respectively, Table 2)
compared to placebo. Also, the absolute number of lym-
phocytes was slightly higher in the IP group (p = 0.042,
0.029 and 0.044 at week 4, 8 and 12, respectively),
which could be related to a slight increase of the abso-
lute number of CD4 cells (p = 0.017, p = 0.009, p =
0.010 and p = 0.031 in week 4, 8, 12 and 16 respec-
tively) and CD8 cells (p = 0.038 in week 12, Table 2).
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6. C-reactive protein was lower in the IP group at follow
up compared to the placebo group (p = 0.018), and
lower in the VM group at 12 weeks treatment and
follow up as compared to the placebo group (p = 0.002
and p = 0.027, respectively).
Immunoglobulin M (IgM) slightly increased in the IP
group compared to the placebo group after 8 and 12
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Figure 1 Flow chart of the study.
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Page 4 of 12weeks treatment (p = 0.033 and 0.022, respectively) and
was also slightly higher in the VM group than in the
placebo group after 4 weeks treatment (p = 0.007). This
increase could, at least in the IP group, possibly be
related to the mistletoe preparations, because IgM also
increased slightly in comparison to baseline, and
because antibody production, measured in week 12, was
stimulated in the IP group. (compared to placebo p <
0.001 for ML- and viscotoxin antibodies). In the VM-
group viscotoxin and ML-antibodies were not signifi-
cantly different to the placebo group. TNF-a was at
week 12 slightly higher in the IP group than in the pla-
cebo group (p = 0.010, Table 2). During exposure, no
differences in absolute neutrophil counts, the number of
natural killer cells, monocytes, T-suppressor cells, B-
cells, immunoglobulins A and G were found for either
IP or VM compared to placebo.
Application of IP strengths G (0.25%] and H (5%)
caused local reactions (LR) at the site of injection in
almost all subjects belonging to the IP-group (93%,
Table 3). LR were strong, with a mean diameter of 2 cm
in week 4, 6.1 cm in week 8, and 6.2 cm in week 12.
Maximum diameter of redness occurred in week 6 (8.8
cm). Because of the strong, in part subjectively not tol-
erated local reactions, dose adjustments had to be per-
formed for IP strengths G and H in line with the
protocol and analogous to procedure in tumor patients
[15]. The total number of ampoules injected was lower
in the IP group compared to placebo (Table 3). Subse-
quently, tolerability of IP strengths G and H was esti-
mated to be worse than placebo (p < 0.0001, Table 3).
VM caused mild local reactions in 19% of the subjects
at concentrations D2 and 2% (diameter up to a mean of
2 cm) and tolerability was also worse than placebo (p =
0.0207, exact two-sided Wilcoxon-Mann-Whitney test,
Table 3). However, dose adjustments were not necessary
(Table 3).
In total, 183 adverse events (AE) were reported
throughout the study, 95 in the IP group, 48 in the VM
group and 40 in the placebo group. Local reactions were
the most frequently reported AE and appeared in 28
from 30 subjects in the IP group, 5 from 21 subjects in
the VM group and 0 from 20 subjects in the placebo
group (Table 3). Also swollen lymph nodes were
reported more frequently in the IP group (Table 4). A
certain relation to the study medication was stated in
26% of the AE in the IP group, 10% in the VM group
and 0% in the placebo group. Only local reactions and
related side effects (swelling of local lymph nodes, loca-
lized itching, local pain of the abdominal wall, fever)
had been classified as probably or certainly related to
the study medication. Two serious AE occurred. One
subject developed acute lumboischialgia (VM group)
and one presented acute gastroenteritis (placebo group).
Both needed hospitalisation. In both cases there was no
relation to the study medication and both subjects con-
tinued the study without deblinding. Coded non serious
AE (according to the Medical Dictionary for Regulatory
Activities (MedDRA) terminology “low level term”)i n
the three groups are shown in Table 4. Vital signs (body
temperature, blood pressure and pulse rate, table 5) and
physical findings (data not shown) were similar in the
different groups. Laboratory parameters (except immu-
n o l o g y )a r es h o w ni nT a b l e6. For most parameters no
differences could be found between the IP and the pla-
cebo group or between the VM and the placebo group.
Neither could any differences at all be shown when the
laboratory parameters were grouped into ‘normal or
without clinical relevance’ and ‘clinical significance with
relevance’. This is supported by the fact that almost no
group values exceeded the reference values.
The only group mean outside the reference values was
the creatine kinase level in the VM group at week 8
with a group mean of 657 U/l. It was caused by one
very high value of 11811 U/l from a subject who trained
mountain biking the day before. The subsequent CK-
level under continued application of the study medica-
tion after 12 weeks was normal (118 U/l). The second
highest CK-value lay with 254 U/l outside the reference
values, too, but the third highest value lay inside the
reference range (154 U/l).
With regards to the logarithmic values of alkaline
p h o s p h a t a s ead i f f e r e n c ec ould be shown, between the
IP and the placebo groups at week 12 (p = 0.023) mean-
ing that the value in the IP group was a little higher in
comparison to the placebo group. The difference is
related to a decrease of this parameter in the placebo
group and not to an increase in the IP group. The
values at baseline were not different to values after 12
weeks treatment or follow up in the IP group. All the
values were well within the normal range (upper limit of
normal = 129 U/l, highest value measured = 126 U/l).
With respect to blood glucose differences could be
shown between the IP and the placebo group after 4
weeks treatment (p = 0.040). The mean values were
smaller in the IP group. Four values out of 29 values in
the IP group were below the lower limit of normal (70
mg/dl), the lowest being 48 mg/dl. In comparison, in
the placebo group, two of 20 values were below the
Table 1 Characteristics of the subjects (percentage or
mean ± standard deviation)
IP (n = 30) VM (n = 21) Placebo (n = 20)
Male/female (%) 40/60 29/71 34/66
Age (years) 29 ± 7 30 ± 7 29 ± 7
BMI (kg/m
2) 2 2±3 2 2±2 2 2±3
Smokers (%) 17 19 30
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®
Populi (IP), Viscum Mali e planta tota (VM) and placebo (Pl) in the ITT population, nd = not done
Group Baseline Exposure Exposure Exposure Follow-up
Week 4 Week 8 Week 12 Week 16
Leukocytes (1000/μl) IP 6.2 ± 2.0 5.9 ± 1.2 7.2 ± 2.0 * 6.7 ± 1.6 * 5.8 ± 1.5
VM 5.7 ± 1.4 5.8 ± 1.2 6.0 ± 1.2 5.6 ± 1.4 5.7 ± 1.0
Pl 6.4 ± 1.7 6.2 ± 1.6 6.5 ± 1.7 6.1 ± 1.7 6.5 ± 1.8
Eosinophils (1000/μl) IP 0.1 ± 0.0 0.2 ± 0.1** 1.1. ± 0.7*** 0.8 ± 0.5*** 0.2 ± 0.1
VM 0.1 ± 0.0 0.1 ± 0.0 0.2 ± 0.0* 0.2 ± 0.0** 0.2 ± 0.1
Pl 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1
Neutrophils (1000/μl) IP 3.8 ± 1.7 3.3 ± 0.9 3.7 ± 1.4 3.5 ± 1.3 3.4 ± 1.3 *
VM 3.3 ± 1.1 3.3 ± 0.9 3.5 ± 1.2 3.2 ± 1.1 3.3 ± 0.7
Pl 3.9 ± 1.5 3.8 ± 1.3 4.0 ± 1.4 3.8 ± 1.6 4.1 ± 1.5
Lymphocytes (1000/μl) IP 1.9 ± 0.5 2.0 ± 0.4* 2.1 ± 0.5* 2.0 ± 0.5* 1.9 ± 0.5
VM 1.9 ± 0.6 2.0 ± 0.5 1.9 ± 0.5 1.9 ± 0.5 1.9 ± 0.6
Pl 1.9 ± 0.3 1.9 ± 0.4 1.9 ± 0.4 1.8 ± 0.3 1.8 ± 0.3
Monocytes (1000/μl) IP 0.4 ± 0.1 0.3 ± 0.0 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.0**
VM 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.1 0.3 ± 0.1 0.3 ± 0.1
Pl 0.3 ± 0.1 0.3 ± 0.0 0.3 ± 0.1 0.3 ± 0.1 0.4 ± 0.1
Natural killer cells (1000/μl) IP 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1
VM 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.0 0.2 ± 0.1 0.2 ± 0.1
Pl 0.3 ± 0.0 0.3 ± 0.0 0.3 ± 0.1 0.2 ± 0.0 0.2 ± 0.0
CD4 cells (1000/μl) IP 0.8 ± 0.3 0.9 ± 0.3* 0.9 ± 0.3* 0.9 ± 0.3* 0.9 ± 0.3*
VM 0.8 ± 0.2 0.9 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 0.8 ± 0.3
Pl 0.9 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.8 ± 0.1 0.8 ± 0.2
CD8 cells (1000/μl) IP 0.4 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1* 0.5 ± 0.1
VM 0.5 ± 0.2 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.1 0.5 ± 0.1
Pl 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1
Ratio T4/T8 IP 2.0 ± 0.7 2.0 ± 0.7* 2.0 ± 0.7 2.0 ± 0.7 2.0 ± 0.7
VM 1.7 ± 0.7 1.8 ± 0.7 1.8 ± 0.7 1.8 ± 0.7 1.8 ± 0.6
Pl 1.8 ± 0.5 1.8 ± 0.5 1.8 ± 0.5 1.9 ± 0.6 1.8 ± 0.5
B-cells (1000/μl) IP 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.2 ± 0.1
VM 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.1 0.2 ± 0.0 0.2 ± 0.0
Pl 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.1
Immunoglobulin A (g/l) IP 1.9 ± 0.7 1.8 ± 0.7 1.8 ± 0.7 1.8 ± 0.7 1.8 ± 0.7
VM 2.2 ± 0.9 2.2 ± 0.8 2.2 ± 0.9 2.2 ± 0.9 2.2 ± 0.8
Pl 1.9 ± 0.7 1.9 ± 0.7 1.9 ± 0.7 1.9 ± 0.7 1.8 ± 0.7
Immunoglobulin G (g/l) IP 11.3 ± 2.4 11.1 ± 2.3 11.0 ± 2.1 11.1 ± 2.2 11.1 ± 2.4
VM 11.1 ± 1.8 11.2 ± 1.7 11.1 ± 1.9 11.1 ± 1.7 11.0 ± 1.7
Pl 11.0 ± 2.4 11.0 ± 2.3 11.0 ± 2.4 11.0 ± 2.3 11.0 ± 2.4
Immunoglobulin M (g/l) IP 1.3 ± 0.5 1.3 ± 0.5 1.3 ± 0.5 1.3 ± 0.5* 1.3 ± 0.6*
VM 1.3 ± 0.6 1.3 ± 0.7** 1.3 ± 0.7 1.3 ± 0.6 1.3 ± 0.6
Pl 1.2 ± 0.6 1.2 ± 0.6 1.2 ± 0.6 1.1 ± 0.6 1.2 ± 0.6
Interleukin-6 (pg/ml) IP 0.8 ± 0.8 0.6 ± 0.3 0.9 ± 1.3 1.3 ± 1.7 0.7 ± 0.5
VM 0.6 ± 0.4 0.5 ± 0.2 1.0 ± 1.2 0.6 ± 0.4 0.6 ± 0.4
Pl 1.0 ± 0.7 0.8 ± 0.7 0.9 ± 0.8 1.0 ± 0.8 1.7 ± 3.0
C-reactive protein (mg/l) IP 2.7 ± 4.4 1.8 ± 1.1 2.1 ± 1.4 3.6 ± 5.5 1.6 ± 1.2*
VM 2.5 ± 3.0 1.8 ± 1.1 3.4 ± 3.5 1.6 ± 1.2** 1.8 ± 1.2*
PL 4.6 ± 9.2 3.0 ± 3.4 3.0 ± 2.6 4.2 ± 3.4 4.3 ± 5.0
Tumor necrosis factor-alpha (ng/l) IP 10 ± 3 10 ± 3 11 ± 3 12 ± 3 * 11 ± 3
VM 10 ± 3 10 ± 3 11 ± 4 11 ± 4 11 ± 3
Pl 10 ± 3 10 ± 2 11 ± 3 10 ± 2 11 ± 2
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Page 6 of 12reference value after 4 weeks treatment, with a mini-
mum value of 68 mg/dl. None of the low glucose con-
centrations was accompanied by clinical symptoms.
Therefore, the low glucose concentrations are most
likely related to a delayed sample analyses, because it is
well known that glucose concentrations rapidly decrease
in blood samples (6 mg/dl per hour at room tempera-
ture)[19].
After 4 weeks treatment, differences were seen
between the VM and placebo group with regard to the
natural logarithm of aspartate aminotransferase (ALT)
levels (p = 0.007). The values were smaller in the VM
group. Lower ALT values have no clinical relevance.
Prothrombin time showed a decrease in the IP com-
pared to the placebo group at follow up (p = 0.026), but
all values were within normal limits. The difference is
related to an increase of this parameter in the placebo
group rather to a decrease in the IP group.
Total bilirubin showed a difference between the VM-
and placebo group (p = 0.036) after 12 weeks treatment
with higher values in the VM group. A total of 5 pro-
bands had intermittently or constantly elevated bilirubin
levels (3 in the VM and 2 in the placebo group) up to a
maximum of 1.9 mg/dl (normal range up to 1.2 mg/dl).
These elevated levels are most likely related to subjects
with Gilbert’s syndrome. Gilbert’ss y n d r o m ei sad i s t u r -
bance of bilirubin glucuronidation, which frequently
(about 5% of the population), causes fluctuating biliru-
bin levels and has no clinical significance [20]. Clinical
examinations and other parameters of the liver function
(prothrombin time) and integrity of the liver cell (ALT,
AST) are normal in subjects with Gilbert’ss y n d r o m e
and were normal in our subjects with isolated elevation
of the bilirubin level. Furthermore, at baseline, bilirubin
levels in all of these 5 subjects were already close to or
slightly above the upper limit of normal without any
clinical or other laboratory sign of liver disease.
After 12 weeks treatment differences of platelet count
were observed between the IP and the placebo group (p
= 0.034) and between the VM and the placebo group (p
= 0.014) with smaller values in the IP and VM group.
However, there was no systematic change and values
also strongly fluctuated in the placebo group.
Discussion
The placebo-controlled, 3-armed modified phase 1 trial
presented here was planned and conducted according to
all current standards. Randomization was concealed and
successful: the groups were well balanced at baseline.
The number of missing data is very low: all but one pro-
band completed the study regularly. All parameters were
analyzed and reported as planned in the study protocol.
There was, therefore, no risk of bias regarding sequence
generation, allocation, incomplete or selective outcome
reporting. Known from the literature, partial deblinding
occurred, because local reactions indicated treatment
with one of the mistletoe preparations [21]. However, the
study remained partially blinded, because not all of the
individuals receiving Viscum Mali e planta tota (VM) or
Iscucin
® Populi (IP) developed local reactions. Further-
more, all analyses of safety laboratory and immunological
parameters were performed blinded. Therefore, partial
deblinding most likely did not affect the results.
The primary aim of the study was to investigate for
the first time safety and tolerability of the two mistletoe
preparations IP and VM in humans to fulfil the require-
ments of the German regulatory authority (BfArM).
Therefore, the preparations were injected in a dose esca-
lating manner.
In order to achieve high internal validity the study was
performed in healthy subjects. Whether or not these
data are transferable to tumor patients is a matter of
debate. Because tumor patients are confronted with a
life threatening disease and often experience severe side
effects from conventional therapy, it can be speculated
that tolerance to harmless local reactions at the site of
injection is higher than in healthy individuals. This well
known side effect of IP which is also mentioned in the
Investigator’s Brochure [15] and in a review about other
mistletoe preparations [22] probably plays a lesser role
in clinical practice than suggested from our study with
healthy subjects. At least the strong local reactions and
f r e q u e n c yo fd o s ea d j u s t m e n ts in our study show, that
w eu s e dt h em a x i m u mt o l e r a b l ed o s ea n dt h a tt h ed a t a
are not biased by under-dosing.
Our data show, that IL-6 serum levels did not increase
after subcutaneous injection of the mistletoe preparations
Table 2 Means ?±? standard deviation of immunological parameters before, during and after exposition with Iscucin
®?
®? Populi (IP), Viscum Mali e planta tota (VM) and placebo (Pl) in the ITT population, nd = not done (Continued)
Mistletoe lectin antibodies (optical density) IP nd nd nd 971 ± 143*** nd
VM nd nd nd 51 ± 31 nd
Pl nd nd nd 33 ± 30 nd
Viscotoxin antibodies (optical density) IP nd nd nd 544 ± 289*** nd
VM nd nd nd 76 ± 98 nd
Pl nd nd nd 13 ± 9 nd
* p < 0.05 compared to placebo, ** p < 0.01 compared to placebo, *** p < 0.001 compared to placebo. Significant deviations are bold typed.
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Page 7 of 12IP and VM. IL-6 was measured with highly sensitive
methods and under strict adherence to the pre-analytic
requirements [19]. It was measured in parallel to the
other immunological parameters and in parallel to the
occurrence of local reactions at the injection site. There-
fore, the results can be regarded as valid, despite the
short half-life of IL-6 in blood. This is supported by the
fact that CRP, which is induced by IL-6 in the liver and
has a longer half-life of 19 h, was also not increased dur-
ing application of the mistletoe preparations. Even if we
would have missed a temporary systemic increase of IL-
6, CRP would have been reacted.
In multiple myeloma patients IL-6 is often synthesized
by the tumor itself and by bone marrow stem cells
within an autocrine growth loop [23]. We of course can-
not rule out, that mistletoe preparations interfere in this
loop, because we investigated healthy probands. But we
can at least conclude that no substantial amounts of IL-
6 are produced from the normal immune system after
application of different dosages IP or VM.
IP strength H has a high mistletoe lectin (ML) content
of about 5300 ng/ml [14]. Because ML are responsible
for the most dominant immunological effects of mistle-
toe preparations in vivo [18], our results are most likely
also transferable to other mistletoe preparations with
related ML-content. Other smaller studies investigating
other mistletoe preparations are in accordance with our
findings ([24-26], for review see [27]) For example in 8
Table 3 Extent of exposure (maximum 24 ampoules = 100%), percentage of subjects with local reactions and
tolerability.
Iscucin
® Populi Viscum Mali e planta tota Placebo
(n = 30) (n = 21) (n = 20)
0.0125% 0.25% 5% 1:1000 1:100 1:50
strength strength strength D3 D2 2%
FGH
Week Week Week Week Week Week Week Week Week
1-4 5-8 9-12 1-4 5-8 9-12 1-4 5-8 9-12
Overall injected ampoules (%) 100.0 81.7 64.0 100.0 100.0 99.1 99.7 99.8 99.9
Local reactions % 17 93 93 0 19 19 0 0 0
Tolerability (%) ** ** *
Bad 0 28 21 00 0 000
Moderate 3 38 45 00 0 500
Good 21 34 34 51 4 29 000
Excellent 76 00 95 86 71 95 100 100
*p < 0.05 versus Placebo, **p < 0.001 versus Placebo. Significant deviations are bold typed.
Table 4 Adverse events as percentage of subjects per group during the three treatment blocks
Iscucin
® Populi Viscum Mali e planta tota Placebo
(n = 30) (n = 21) (n = 20)
Description of AE 0.0125% 0.25% 5% 1:1000 1:100 1:50
strength strength strength D3 D2 2%
FGH
Week Week Week Week Week Week Week Week Week
1-4 5-8 9-12 1-4 5-8 9-12 1-4 5-8 9-12
Abdominal pain (%) 0 3 3 0 0 0 0 0 0
Common cold (%) 27 17 17 38 14 10 15 15 25
Diarrhea (%) 0 3 0 0 0 0 0 0 0
Dizziness (%) 0 3 0 0 0 0 5 0 0
Fatigue (%) 0 0 3 0 0 0 0 0 0
Fever (%) 0 3 0 0 0 0 0 0 0
Headache (%) 13 0 3 14 5 10 5 10 10
Nausea (%) 0 3 3 0 0 0 0 0 0
Swollen lymph nodes (%) 0 3 7 0 0 0 0 0 0
Vomiting (%) 3 3 0 0 0 0 0 0 0
Weakness (%) 0 0 0 5 0 0 5 0 0
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Page 8 of 12breast cancer patients 10 weeks subcutaneous treatment
with 0.2 mg/30 kg of the mistletoe preparation Abnoba-
Viscum Mali (approximately 75 ng/ml/30 kg ML) did
not result in systematic changes of IL-6 concentration
in supernatants of un-stimulated and stimulated periph-
eral mononuclear cells before and during treatment
compared to baseline [25]. In only one small clinical
study presenting 4 not further described individuals [28]
in part increasing IL-6 levels after single injections of
mistletoe extract have been described. However, due to
the poor reporting quality and selection, the validity of
this report is limited.
Interestingly, despite the absence of IL-6 stimulation,
we found significant immunological changes during
treatment with IP, namely a dose dependent, distinct
increase of eosinophils. Eosinophilia during mistletoe
therapy has been described before and is related to the
content of ML in the extracts [16,18,29]. However, a
mean tenfold increase as observed in the present study
has not yet been reported in a clinical study. Because
eosinophils are stimulated by T-helper-2 cells, which
produce IL-5 and simultaneously stimulate B-cells [30],
it is plausible that the number of CD4 cells and IgM
were increased in the IP group.
Eosinophils have cytotoxic properties and may play a
role in the host response against cancer [31,32]. There
exists evidence from epidemiological studies, that eosi-
nophilia correlates with a better prognosis in a variety
of cancer types ([33,34] for review see [32]). Whether or
not eosinophilia has a clinical benefit for cancer patients
during treatment with IP requires further investigation.
VM caused only a mild increase of eosinophils in some
individuals treated with strength D2 and 2%.
In order not to miss a potential risk, a comprehensive
safety analysis was performed. Several group differences
were found between the two mistletoe preparations and
placebo and single values were outside the reference
range. However, conspicuous values could be explained
by reasons unrelated to the study medication, e.g.
elevated creatine kinase levels after exercise, low glucose
due to transport time and intermittent elevations of
bilirubin due to Gilbert’s syndrome, which has no clini-
cal significance. At single visits, C-reactive protein and
alanine aminotransferase (ALT) levels were in the mis-
tletoe groups significantly different from placebo, how-
ever, the values were higher in the placebo group.
Prothrombin time and platelet count were significantly
lower in the IP or VM group at single visits. Because
values remained within normal limits and no systematic
changes were found, the differences are most likely
related to multiple testing. Performing 100 statistical
comparisons on a significance level of 5% automatically
generates a risk of 5 false results. For the parameters in
t a b l e6a l o n ew ep e r f o r m e d1 8 8s t a t i s t i c a lc o m p a r i s o n s
(25 laboratory parameters, except prothrobin time and
thromboplastin time each tested at 4 time points for the
two mistletoe preparations versus placebo), resulting in
a probability of 9 false results. We had exactly 9 signifi-
cant group differences at single visits regarding the para-
meters in table 6, which is in the expected range. In
addition to significant group differences we carefully
searched for systematic deviations and values outside
the normal range but also this strategy did not reveal a
potential risk of the two mistletoe preparations. Because
our analysis revealed no hint for side effects of the
tested preparations on liver, kidney, respiratory, gastro-
intestinal, cardiovascular and nervous system and no
suppressive effects on bone marrow- or immune func-
tions could be found, the risk of side effects on inner
organs is therefore most likely to be negligible in tumor
patients, too.
Nevertheless, local reactions from application of IP
strengths G and H can be strong. Therefore, a whole
ampoule of IP strength G or H should preferably only
be used in patients who have been pre-treated with
lower doses of IP to induce tolerance. Local reactions
are related to the preparation’s mistletoe lectin (ML)
content. This relationship has been shown in other
Table 5 Vital signs (means ± standard deviation) in the ITT population.
Group Baseline Exposure Exposure Exposure Follow-up
Week 4 Week 8 Week 12 Week 16
Body temperature IP 36.4 ± 0.4 36.4 ± 0.4 36.3 ± 0.5 36.4 ± 0.4 36.5 ± 0.3
VM 36.5 ± 0.4 36.2 ± 0.5 36.3 ± 0.5 36.3 ± 0.3 36.4 ± 0.3
PL 36.3 ± 0.4 36.3 ± 0.3 36.4 ± 0.4 36.4 ± 0.3 36.5 ± 0.4
Systolic blood pressure IP 120 ± 11 117 ± 11 114 ± 10 117 ± 11 112 ± 12
VM 112 ± 10 114 ± 10 110 ± 11 111 ± 12 112 ± 13
PL 112 ± 13 110 ± 11 113 ± 9 111 ± 13 112 ± 13
Heart rate IP 76 ± 11 72 ± 7 74 ± 9 71 ± 9 72 ± 11
VM 71 ± 9 74 ± 11 70 ± 8 68 ± 8 66 ± 9
PL 74 ± 8 71 ± 9 72 ± 6 72 ± 9 74 ± 7
IP = Iscucin
® Populi, VM = Viscum Mali e planta tota, PL = placebo.
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Page 9 of 12Table 6 Laboratory parameters (means ± standard deviation) in the ITT population.
Group Baseline Exposure Exposure Exposure Follow-up
Week 4 Week 8 Week 12 Week 16
Hemoglobin (mg/dl) IP 14.0 ± 1.0 14.0 ± 0.9 13.9 ± 1.0 14.0 ± 0.9 14.0 ± 0.9
VM 13.6 ± 1.1 13.7 ± 1.0 13.7 ± 1.0 13.5 ± 1.1 13.6 ± 1.1
PL 13.8 ± 0.9 13.8 ± 1.0 14.0 ± 1.1 13.8 ± 1.1 13.8 ± 1.1
Hematocrit (%) IP 41.6 ± 2.6 41.7 ± 2.4 41.2 ± 2.6 41.4 ± 2.5 41.4 ± 2.1
VM 40.7 ± 2.8 41.1 ± 2.7 40.7 ± 2.9 40.4 ± 3.1 40.5 ± 2.8
PL 41.4 ± 2.1 41.4 ± 2.5 41.8 ± 2.7 41.3 ± 2.7 41.4 ± 2.8
Platelets (1000/μl) IP 272 ± 52 259 ± 43 271 ± 44 256 ± 41* 250 ± 44
VM 269 ± 46 272 ± 62 260 ± 59 251 ± 55* 256 ± 65
PL 267 ± 56 265 ± 52 274 ± 66 271 ± 56 254 ± 52
Calcium (mmol/l) IP 2.4 ± 0.0 2.4 ± 0.1 2.4 ± 0.0 2.4 ± 0.0 2.4 ± 0.0
VM 2.3 ± 0.0 2.4 ± 0.1 2.4 ± 0.0 2.4 ± 0.0 2.4 ± 0.1
PL 2.4 ± 0.0 2.4 ± 0.0 2.4 ± 0.0 2.4 ± 0.0 2.4 ± 0.1
Potassium (mmol/l) IP 4.3 ± 0.2 4.3 ± 0.4 4.3 ± 0.3 4.2 ± 0.3 4.2 ± 0.2
VM 4.3 ± 0.3 4.1 ± 0.2 4.2 ± 0.2 4.2 ± 0.2 4.3 ± 0.2
PL 4.3 ± 0.2 4.2 ± 0.2 4.3 ± 0.3 4.3 ± 0.3 4.4 ± 0.4
Sodium (mmol/l) IP 139 ± 2 139 ± 2 141 ± 2 140 ± 2 141 ± 2
VM 139 ± 1 139 ± 2 141 ± 1 140 ± 2 140 ± 1
PL 138 ± 2 139 ± 1 141 ± 2 140 ± 2 141 ± 2
Chloride (mmol/l) IP 101 ± 2 102 ± 2 103 ± 2 102 ± 2 102 ± 2
VM 102 ± 2 102 ± 2 104 ± 1 103 ± 2 103 ± 2
PL 101 ± 2 102 ± 2 104 ± 2 103 ± 2 103 ± 2
Creatinine (mg/dl) IP 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
VM 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
PL 0.8 ± 0.0 0.8 ± 0.1 0.8 ± 0.0 0.8 ± 0.1 0.8 ± 0.1
Urea (mg/dl) IP 26 ± 6. 28 ± 7 28 ± 8* 27 ± 6 28 ± 6
VM 26 ± 7 28 ± 8 28 ± 7* 29 ± 8 27 ± 7
PL 30 ± 8 27 ± 6 26 ± 7 29 ± 8 30 ± 7
Uric acid (mg/dl) IP 4.3 ± 1.0 4.5 ± 0.9 4.3 ± 1.1 4.3 ± 1.1 4.6 ± 1.1
VM 4.2 ± 1.0 4.2 ± 0.8 4.1 ± 0.8 4.2 ± 0.9 4.2 ± 1.0
PL 4.3 ± 0.9 4.3 ± 1.1 4.3 ± 1.1 4.5 ± 1.3 4.6 ± 1.1
AST (U/l) IP 26 ± 8 25 ± 7 25 ± 9 25 ± 7 26 ± 7
VM 25 ± 6 23 ± 5 37 ± 60 25 ± 6 25 ± 7
PL 26 ± 7 24 ± 7 23 ± 6 23 ± 6 26 ± 10
ALT (U/l) IP 20 ± 10 18 ± 7 16 ± 7 16 ± 7 17 ± 8
VM 20 ± 9 17 ± 6** 2 0±1 6 1 7±8 1 7±8
PL 20 ± 10 21 ± 13 19 ± 16 18 ± 14 19 ± 12
Gamma GT (U/l) IP 19 ± 9 18 ± 7 20 ± 9 19 ± 9 19 ± 9
VM 15 ± 6 15 ± 6 15 ± 5 15 ± 5 14 ± 5
PL 19 ± 10 20 ± 11 21 ± 12 20 ± 12 18 ± 12
Alkaline phosphatase (U/l) IP 63 ± 20 61 ± 20 64 ± 19 64 ± 18* 63 ± 21
VM 56 ± 17 56 ± 14 58 ±15 54 ± 12 54 ± 14
PL 59 ± 14 59 ± 17 58 ±16 57 ± 14 58 ± 19
Bilirubin (mg/dl) IP 0.6 ± 0.2 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.2
VM 0.6 ± 0.3 0.7 ± 0.3 0.6 ± 0.3 0.7 ± 0.3* 0.6 ± 0.3
PL 0.6 ± 0.3 0.6 ± 0.3 0.6 ± 0.5 0.6 ± 0.2 0.6 ± 0.3
Total protein (g/dl) IP 7.7 ± 0.5 7.8 ± 0.4 7.7 ± 0.3 7.8 ± 0.4 7.8 ± 0.6
VM 7.5 ± 0.3 7.8 ± 0.3 7.6 ± 0.3 7.6 ± 0.3 7.7 ± 0.3
PL 7.6 ± 0.2 7.7 ± 0.2 7.7 ± 0.3 7.7 ± 0.3 7.6 ± 0.3
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development of ML-antibodies [16,18]. In the present
study, ML-antibodies also formed in the IP-treated sub-
jects and local reactions (week 6 = 8.9 cm) declined
with prolonged treatment (week 12 = 6.2 cm) although
the amount of injected mistletoe extract was increased.
High doses of other mistletoe preparations causing simi-
lar strong local reactions have been clinically used with
beneficial effects for the treatment of hepatocellular car-
cinoma with beneficial effects [35]. These data provide
justification for further investigation of the effects of
highly concentrated mistletoe preparations. VM does
not cause strong local reactions and was very well toler-
ated at all dose levels.
Conclusion
Iscucin
® Populi is a strong stimulator of eosinophils,
probably generated via a T-helper-2 cell activation. It
does not have immunosuppressive effects or stimulate
markers of inflammation like C-reactive protein or IL-6
production. Viscum Mali e planta tota promotes only a
mild increase of eosinophils and is well tolerable.
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Table 6 Laboratory parameters (means ?±? standard deviation) in the ITT population. (Continued)
Albumin (g/dl) IP 4.7 ± 0.3 4.7 ± 0.2 4.7 ± 0.2 4.7 ± 0.2 4.7 ± 0.3
VM 4.6 ± 0.2 4.7 ± 0.2 4.7 ± 0.2 4.6 ± 0.2 4.6 ± 0.2
PL 4.6 ± 0.2 4.7 ± 0.2 4.6 ± 0.3 4.6 ± 0.2 4.5 ± 0.3
Lactate Dehydrogenase (U/l) IP 185 ± 23 179 ± 26 189 ± 36 200 ± 32 189 ± 34
VM 180 ± 30 172 ± 35 184 ± 78 179 ± 37 184 ± 34
PL 191 ± 24 186 ± 32 180 ± 29 191 ± 28 197 ± 26
Creatine kinase (U/l) IP 124 ± 78 126 ± 70 149 ± 192 152 ± 113 141 ± 107
VM 118 ± 89 139 ± 114 657 ± 2556 134 ± 75 127 ± 112
PL 163 ± 225 140 ± 212 112 ± 83 126 ± 89 197 ± 379
Amylase (U/l) IP 31 ± 8 31 ± 9 30 ± 9 30 ± 8 30 ± 8
VM 35 ± 11 35 ± 12 34 ± 10 33 ± 11 34 ± 11
PL 35 ± 9 34 ± 8 34 ± 8 33 ± 7 32 ± 8
Glucose (mg/dl) IP 89 ± 18 81 ± 12* 84 ± 14 82 ± 12 83 ± 13
VM 89 ± 16 82 ± 10 83 ± 9 85 ± 11 85 ± 16
PL 81 ± 10 89 ± 18 86 ± 19 85 ± 20 89 ± 15
Cholesterol (mg/dl) IP 178 ± 27 192 ± 26 177 ± 26 176 ± 26 192 ± 29
VM 178 ± 25 194 ± 32 183 ± 29 185 ± 28 193 ± 26
PL 191 ± 44 200 ± 48 194 ± 48 192 ± 45 203 ± 43
Triglycerides (mg/dl) IP 116 ± 86 117 ± 68 108 ± 71 121 ± 101 109 ± 73
VM 86 ± 33 94 ± 38 87 ± 46 87 ± 40 86 ± 32
PL 123 ± 65 120 ± 52 121 ± 56 110 ± 48 124 ± 66
Thromboplastin time (sec) IP 30 ± 3 nd nd nd 30 ± 3
VM 30 ± 3 nd nd nd 30 ± 3
PL 31 ± 3 nd Nd nd 30 ± 4
Prothrombin time (%) IP 106 ± 13 nd nd nd 105 ± 11*
VM 108 ± 12 nd nd nd 108 ± 10
PL 107 ± 11 nd nd nd 109 ± 11
IP = Iscucin
® Populi, VM = Viscum Mali e planta tota, PL = placebo, nd = not done.
* p < 0.05 compared to placebo, ** p < 0.01 compared to placebo. Significant deviations are bold typed.
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